JP2011513288A5 - - Google Patents

Download PDF

Info

Publication number
JP2011513288A5
JP2011513288A5 JP2010548176A JP2010548176A JP2011513288A5 JP 2011513288 A5 JP2011513288 A5 JP 2011513288A5 JP 2010548176 A JP2010548176 A JP 2010548176A JP 2010548176 A JP2010548176 A JP 2010548176A JP 2011513288 A5 JP2011513288 A5 JP 2011513288A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
optionally substituted
group
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010548176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011513288A (ja
JP5555186B2 (ja
Filing date
Publication date
Priority claimed from GB0803748A external-priority patent/GB0803748D0/en
Priority claimed from GB0815544A external-priority patent/GB0815544D0/en
Application filed filed Critical
Priority claimed from PCT/GB2009/000553 external-priority patent/WO2009106844A1/en
Publication of JP2011513288A publication Critical patent/JP2011513288A/ja
Publication of JP2011513288A5 publication Critical patent/JP2011513288A5/ja
Application granted granted Critical
Publication of JP5555186B2 publication Critical patent/JP5555186B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010548176A 2008-02-29 2009-02-27 p38MAPキナーゼ阻害剤 Expired - Fee Related JP5555186B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0803748A GB0803748D0 (en) 2008-02-29 2008-02-29 Ihibitors of p38 MAP kinase
GB0803748.3 2008-02-29
GB0815544A GB0815544D0 (en) 2008-08-27 2008-08-27 Inhibitors of p38 map kinase
GB0815544.2 2008-08-27
PCT/GB2009/000553 WO2009106844A1 (en) 2008-02-29 2009-02-27 Inhibitors of p38 map kinase

Publications (3)

Publication Number Publication Date
JP2011513288A JP2011513288A (ja) 2011-04-28
JP2011513288A5 true JP2011513288A5 (cg-RX-API-DMAC7.html) 2012-04-12
JP5555186B2 JP5555186B2 (ja) 2014-07-23

Family

ID=40585513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010548176A Expired - Fee Related JP5555186B2 (ja) 2008-02-29 2009-02-27 p38MAPキナーゼ阻害剤

Country Status (5)

Country Link
US (1) US8778953B2 (cg-RX-API-DMAC7.html)
EP (1) EP2245012B1 (cg-RX-API-DMAC7.html)
JP (1) JP5555186B2 (cg-RX-API-DMAC7.html)
ES (1) ES2427892T3 (cg-RX-API-DMAC7.html)
WO (1) WO2009106844A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007129040A1 (en) * 2006-05-04 2007-11-15 Chroma Therapeutics Ltd. p38 MAP KINASE INHIBITORS
GB0803747D0 (en) * 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
BR112015008167B1 (pt) 2012-10-17 2020-11-17 Macrophage Pharma Limited composto, composição farmacêutica, métodos para a inibição da atividade de uma enzima quinase map p38, para o tratamento ou a prevenção de doença autoimune ou inflamatória em um indivíduo, e para o tratamento, a melhoria ou a redução da incidência de doença proliferativa de células em um indivíduo, uso de composto, e, ácido
GB201306901D0 (en) * 2013-04-16 2013-05-29 Chroma Therapeutics Ltd Combination
CN116570594A (zh) 2016-06-23 2023-08-11 马里兰大学巴尔的摩分校 选择性p38α特异性MAPK抑制剂
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
CN113395963B (zh) 2018-12-07 2024-06-25 马里兰大学巴尔的摩分校 非ATP/催化位点p38丝裂原活化蛋白激酶抑制剂
US11286260B2 (en) * 2020-05-18 2022-03-29 Gen1E Lifesciences Inc. P38α mitogen-activated protein kinase inhibitors
CN116367838A (zh) 2020-10-29 2023-06-30 Gen1E生命科学公司 结晶5-(二甲基氨基)-n-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物
US11555020B2 (en) 2021-03-23 2023-01-17 Gen1E Lifesciences Inc. Substituted naphthyl p38α mitogen-activated protein kinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5331006A (en) * 1990-08-31 1994-07-19 Warner-Lambert Company Amino acid analogs as CCK antagonists
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US6448256B1 (en) * 1999-05-24 2002-09-10 University Of Massachusetts Antibiotic prodrugs
BR0308429A (pt) * 2002-03-14 2005-01-11 Bayer Healthcare Ag Aroilpiridinonas monocìclicas como agentes antiinflamatórios
EP1633751A1 (en) 2003-06-16 2006-03-15 Chroma Therapeutics Limited Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
SG145693A1 (en) 2003-07-29 2008-09-29 Signature R & D Holdings Llc Amino acid prodrugs
EP3075247B1 (en) 2004-02-02 2022-10-12 BioSight Ltd. Conjugates for cancer therapy and diagnosis
DE602005003951T4 (de) * 2004-05-14 2012-10-11 Millennium Pharmaceuticals, Inc. Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
PL1877098T3 (pl) * 2005-05-05 2013-09-30 Glaxosmithkline Ip Dev Ltd Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazy
WO2007129040A1 (en) * 2006-05-04 2007-11-15 Chroma Therapeutics Ltd. p38 MAP KINASE INHIBITORS
GB0621830D0 (en) 2006-11-02 2006-12-13 Chroma Therapeutics Ltd Inhibitors of p38 mitogen-activated protein kinase
JP2011503042A (ja) 2007-11-07 2011-01-27 クロマ セラピューティクス リミテッド p38MAPキナーゼ阻害剤

Similar Documents

Publication Publication Date Title
JP2011513288A5 (cg-RX-API-DMAC7.html)
CN104918612B (zh) 作为抗hbv感染的抗病毒剂的官能化苯甲酰胺衍生物
JP3634749B2 (ja) α4介在細胞接着阻害剤
JP3795305B2 (ja) 医薬組成物
JP2010505802A5 (cg-RX-API-DMAC7.html)
KR102093608B1 (ko) 이미다조피리딘 화합물
JP2010507639A5 (cg-RX-API-DMAC7.html)
JP2009535385A5 (cg-RX-API-DMAC7.html)
JP2002520309A5 (cg-RX-API-DMAC7.html)
JP2008540390A5 (cg-RX-API-DMAC7.html)
JP2011521979A5 (cg-RX-API-DMAC7.html)
JP2009535387A5 (cg-RX-API-DMAC7.html)
JP2004529161A5 (cg-RX-API-DMAC7.html)
EA200701416A1 (ru) Производные фениламида 4-(бензил)пиперазин-1-карбоновой кислоты и родственные соединения в качестве модуляторов амида жирной кислоты гидролазы для лечения страхов, боли и других состояний
JP2010508336A5 (cg-RX-API-DMAC7.html)
JP2007532651A5 (cg-RX-API-DMAC7.html)
JP2020515583A5 (cg-RX-API-DMAC7.html)
AU2004212494A1 (en) Processes for the preparation of N-heteroaryl-N-aryl-amines by reacting an N-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
JP2013542980A5 (cg-RX-API-DMAC7.html)
JP2012519162A5 (cg-RX-API-DMAC7.html)
CA2439604A1 (en) N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation
JP2011518817A5 (cg-RX-API-DMAC7.html)
RU2004117595A (ru) Производные пиридина в качестве лигандов рецептора nmda
EP0202062A3 (en) Quinuclidine derivatives
JP2005504790A5 (cg-RX-API-DMAC7.html)